Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded
- Contract number
- SPE2DB26FL0C9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $77,050
Award facts
- Contract value 100% obligated
- $77,050.35 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $77,050.35 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 mL autoinjector vials. The award, issued on October 29, 2025, with an ultimate completion date of November 20, 2025, carries no set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. This delivery order was issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to establish regional prime vendor contractors for the Department of Defense's global pharmaceutical supply needs.
DMS Pharmaceutical Group serves as a critical pharmaceutical supplier for military healthcare facilities worldwide, with a primary contract ceiling value of $499,999,999 and a completion date of December 31, 2036. The company's established performance across numerous delivery orders spanning oncology treatments, immunosuppressants, biologics, vaccines, and specialty pharmaceuticals demonstrates its capability to fulfill the diverse medical supply requirements of the federal military medical system. Xolair, a biologic agent used for immunological conditions, represents one of many specialized pharmaceutical products the contractor supplies through its PPV-G GEN V prime vendor agreement.
Quick answers
Who was awarded contract SPE2DB26FL0C9?
SPE2DB26FL0C9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 29, 2025.
How much is contract SPE2DB26FL0C9 worth?
The government has obligated $77,050 on SPE2DB26FL0C9.
Is contract SPE2DB26FL0C9 an order under another contract?
Yes. SPE2DB26FL0C9 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB26FL0C9 competed?
The extent of competition for SPE2DB26FL0C9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award